Viatris Inc (VTRS) Stock Price & Analysis
Viatris Inc (VTRS) rose 1.69% to USD 16.2 as of June 9, 2026 at 23:35 UTC, according to Nexqual real-time market data.
VTRS last closed at USD 15.93; the session ranged USD 15.93–16.41 on volume of 7,816,074 shares. Market capitalization is $18.87B, with a 52-week range of USD 8.63–17.53 (NMS). Source: Nexqual, June 9, 2026 at 23:35 UTC.
Key Statistics (as of June 9, 2026 at 23:35 UTC)
| Price | USD 16.2 |
|---|---|
| Change | ▲ 1.69% (up) |
| Previous Close | USD 15.93 |
| Open | USD 16.13 |
| Day Range | USD 15.93 – 16.41 |
| 52-Week Range | USD 8.63 – 17.53 |
| Volume | 7,816,074 shares |
| Market Cap | $18.87B |
| Exchange | NMS |
Technical Analysis (VTRS)
Nexqual's technical model rates VTRS "BUY" based on 4 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:35 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.84 (neutral) |
| vs SMA50 | Above (USD 15.28) |
| MACD | 0.1 (positive) |
Analyst Ratings (VTRS)
Wall Street analysts rate VTRS "Buy" based on 9 analysts, with a mean price target of USD 18.06 (range USD 12–23), per Nexqual as of June 9, 2026 at 23:35 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 18.06 |
| High Target | USD 23 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 6 / 4 / 1 |
Earnings (VTRS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.6 |
| Revenue Estimate | $3.67B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.59 vs est 0.5 ▲ beat |
| 2025-12-31 | USD 0.57 vs est 0.53 ▲ beat |
| 2025-09-30 | USD 0.67 vs est 0.62 ▲ beat |
| 2025-06-30 | USD 0.62 vs est 0.56 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financials & Fundamentals (VTRS)
| Total Revenue | $14.56B |
|---|---|
| Revenue Growth (YoY) | +8.10% |
| Gross Margin | +39.82% |
| Operating Margin | +6.78% |
| Profit Margin | -2.04% |
| ROE | -1.96% |
| Debt / Equity | 99.68 |
| Current Ratio | 1.6 |
| Total Cash | $2.40B |
| Total Debt | $14.61B |
| Free Cash Flow | $2.24B |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Financial Health Score (VTRS)
Nexqual rates Viatris Inc's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:35 UTC.
| Growth | Weak — Revenue -3% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 40%, operating 7% |
| Balance Sheet | Mixed — $2.40B cash vs $14.6B debt |
| Cash Flow | Strong — FCF $2.24B, 16% margin |
| Efficiency | Critical — ROE -2%, ROA 2.3% |
Ownership (VTRS)
| Insider Ownership | +0.44% |
|---|---|
| Institutional Ownership | +87.32% |
| Shares Outstanding | 1.16B |
| Float | 1.16B |
| Short % of Float | +3.28% |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
Leadership (VTRS)
Viatris Inc is led by Scott Andrew Smith (age 63), CEO & Director, per Nexqual as of June 9, 2026 at 23:35 UTC.
| CEO & Director | Scott Andrew Smith (age 63) |
|---|---|
| Interim CFO, Chief Accounting Officer & Corporate Controller | Paul B. Campbell (age 58) |
Major Backers & Investors (VTRS)
Notable institutional backers of Viatris Inc include Davis Selected Advisers, Price (T.Rowe) Associates Inc, Invesco, according to Nexqual as of June 9, 2026 at 23:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Davis Selected Advisers | 6.72% |
| Price (T.Rowe) Associates Inc | 5.66% |
| Invesco | 2.93% |
| Rubric Capital Management LP | 2.88% |
| DAVIS NEW YORK VENTURE FUND INC-Davis New York Venture Fund | 1.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 20.42% |
| BlackRock | 8.52% |
| State Street | 5.68% |
| Dimensional Fund Advisors | 3.29% |
| Geode Capital | 2.73% |
Source: Nexqual, June 9, 2026 at 23:35 UTC.
From Viatris Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Viatris retained some selective R&D capabilities in API. • In July 2024, the Company completed the divestiture of its OTC Business to Cooper Consumer Health, a leading European OTC drug manufacturer and distributor.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OGN | Organon & Co. | USD 13.4 | ▲ 0.3% |
| WBD | Warner Bros. Discovery, Inc. - | USD 26.56 | ▲ 1.22% |
| CTVA | Corteva, Inc. | USD 75.01 | ▼ 2.62% |
| GEHC | GE HealthCare Technologies Inc. | USD 66.01 | ▲ 2.07% |
| LUMN | Lumen Technologies, Inc. | USD 8.47 | ▼ 4.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:35 UTC. This page is informational and not investment advice.